Description
Key facts
CAS number:1622902-68-4,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:323.42 Da,
Molecular formula:C14H21N5O2S,
PubChem:78323835,
Nature:Synthetic,
Solubility:>10 mg/ml DMSO,
Biochemical name:N-[cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide,
Biological description:Potent, selective, orally bioavailable JAK1 inhibitor (IC₅₀ = 29 nM). It displays excellent selectivity for JAK1 versus other JAK family enzymes.,
Canonical smiles:CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3,
InChi:InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17),
InChiKey:IUEWXNHSKRWHDY-UHFFFAOYSA-N,
IUPAC Name:N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
Product details:
This product is manufactured by BioVision, an Abcam company and was previously called B2470 PF-04965842. B2470-5 is the same size as the 5 mg size of ab287063.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
JAK1 JAK2 JAK3 VEGF Receptor 2 TYK2 and Monoamine Oxidase are significant proteins in various cellular processes. Janus kinases (JAK1 JAK2 JAK3 TYK2) function as non-receptor tyrosine kinases which initiate signaling pathways upon cytokine receptor activation. JAK1 JAK2 and JAK3 have approximate masses of 130 kDa 140 kDa and 125 kDa respectively. VEGF Receptor 2 also known as KDR or FLK1 is a receptor tyrosine kinase integral to vascular endothelial growth factor signaling with a mass around 200 kDa. Monoamine oxidase an enzyme localized in the outer mitochondrial membrane with a mass of approximately 60 kDa is responsible for the degradation of monoamine neurotransmitters. Expression of these proteins varies: JAKs and TYK2 are found widely in different tissues VEGF Receptor 2 is mainly in endothelial cells while Monoamine oxidase existing in two forms MAO-A and MAO-B is expressed in neural and hepatic tissues.
Biological function summary
These proteins regulate essential cellular processes. JAKs engage in cytokine receptor signaling leading to transcriptional activation important for immune response and cell growth. VEGF Receptor 2 mediates angiogenesis and vascular permeability important in forming blood vessels. Monoamine oxidase participates in the breakdown of neurotransmitters like serotonin and dopamine influencing neural communication and mood regulation. These proteins can form part of multi-component signaling complexes; for instance JAKs often associate with Signal Transducers and Activators of Transcription (STAT) proteins to transduce signals from membrane-bound receptors to the nucleus.
Pathways
JAKs and TYK2 are central to the JAK-STAT pathway which transmits extracellular signals to the nucleus impacting gene expression related to immune function and cell division. A related signaling pathway involves VEGF Receptor 2 operating in the PI3K-Akt pathway to mediate survival signals that are essential for endothelial cell function and angiogenesis. Monoamine oxidase also fits into the catecholamine degradation pathway breaking down excess neurotransmitters to prevent oxidative stress and maintain neurochemical balance. Proteins such as STATs phosphatidylinositol 3-kinase (PI3K) and Akt are related through these pathways enabling coordinated cellular responses to various stimuli.
Dysregulation of these proteins associates with significant pathological conditions. JAK2 mutations can lead to myeloproliferative disorders due to uncontrolled cell proliferation linking it to proteins in the JAK-STAT signaling cascade. VEGF Receptor 2 overactivity is implicated in cancer facilitating tumor angiogenesis and it interacts with proteins in the VEGF signaling pathway. Monoamine oxidase deficiencies or abnormalities are connected to neurodegenerative disorders like Parkinson’s disease due to neurotransmitter imbalance interacting with catechol-O-methyltransferase in neurotransmitter degradation. Understanding these connections helps in developing targeted therapies for these conditions.
